Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer

  • Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1

  • New ready-to-dilute format and 1,000 mg strength option helps avoid unnecessary handling steps to reduce associated contamination risks and patient waiting times2

  • The Pemetrexed launch will expand the Sandoz hospital portfolio in key European markets, strengthening access to treatment …
/by